Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study

Abstract Purpose To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (C3F8). Methods Treatment naïve neovascular age related macular degen...

Full description

Saved in:
Bibliographic Details
Main Authors: Debdulal Chakraborty, Tushar Kanti Sinha, Soumen Mondal, Subhendu Boral, Arnab Das, Saptorshi Majumbar, Angshuman Mukherjee, Ranabir Bhattacharya, Sumit Randhir Singh
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Ophthalmology
Subjects:
Neovascular age related macular degeneration
Anti-vascular endothelial growth factor
anti-VEGF
Biosimilar
Biosimilar ranibizumab
Perfluoropropane
Online Access:https://doi.org/10.1186/s12886-025-03846-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12886-025-03846-x

Similar Items